Dr. Holtz has 30 years of experience in the development of bioproducts, biopharmaceuticals, and design of biopharmaceutical manufacturing facilities. Dr. Holtz led the design/build team for construction and commissioning of the iBio facility. Serving 15 years as SVP for Large Scale Biology Corporation, Dr. Holtz led a team that developed and produced a recombinant, plant-made, patient-specific vaccine for the treatment of indolent Non-Hodgkin's Lymphoma from bench to human clinical trials. Dr. Holtz was founder and President of Holtz Bio-Engineering, which developed bioreactor based processes, a proprietary line of bioreactors, and distributed logic control systems for cell culture. Dr. Holtz received his Ph.D. at Pennsylvania State University and was an NSF Postdoctoral Fellow at Scripps Institution of Oceanography. Dr. Holtz has 23 US patents and has published over 60 scientific papers. Dr. Holtz was awarded the Pennsylvania State University, Outstanding Alumni Award in 2003.